Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 2/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.41 |
| ▸ | TTK | P33981 | 1/20 | 0.41 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.41 |
| ▸ | BTK | Q06187 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26936207 | 0.80 | PGR (0.48) | PGRCYP19A1GSK3BPRMT5WDR77 | |
| SCHEMBL7920867 | 0.79 | CYP19A1 (0.52) | PGRCYP19A1CASP3SENP7SENP6 | |
| SCHEMBL22172016 | 0.79 | CASP3 (0.53) | PGRCYP19A1CASP3SENP7SENP6 | |
| SCHEMBL14733823 | 0.78 | CYP1A2 (0.56) | PGRCYP19A1GSK3BPIM1PIM2 | |
| SCHEMBL1999586 | 0.78 | PGR (0.46) | PGRCYP19A1PRMT5WDR77PIM1 | |
| SCHEMBL29293277 | 0.77 | CYP19A1 (0.54) | PGRCYP19A1GSK3BPIM1PIM2 | |
| SCHEMBL12129586 | 0.74 | PGR (0.58) | PGRCYP19A1GSK3BPIM1PIM2 | |
| SCHEMBL13383503 | 0.73 | CYP2A6 (0.48) | PGRCYP19A1PRMT5WDR77PIM1 | |
| SCHEMBL26936255 | 0.72 | PGR (0.46) | PGRCYP19A1CASP3SENP7SENP6 | |
| SCHEMBL23331717 | 0.72 | CYP11B1 (0.50) | PGRCYP19A1GSK3BPIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883782-B2 | Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2328903-B1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE | AMGEN INC (US) | 2014-03-05 | — | — | EP | disclosed |
| US-8426447-B2 | Spiro-tricyclic ring compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2547685-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS | Amgen Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011115938-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS | AMGEN INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| EP-2328903-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-04-08 | — | — | US | disclosed |
| WO-2010030954-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | PGR 3137/4885CYP19A1 152/4885CASP3 1115/4885 |
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | PGR 3125/4885CYP19A1 84/4885CASP3 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.